Archive - Colorado Cancer Blogs

Jean Mulcahy-Levy, MD, earns R01 grant to improve pediatric brain cancer treatment

Jul 8, 2019

Clinical trial hopes to expand use of anti-autophagy drugs in brain cancer

Ben Walburn: All the Time in the World

Jul 2, 2019

By the time you read this, Ben Walburn will almost certainly have passed. Now, in early May, I don’t know if he will use a prescription to end his life. I also don’t know that it matters.

With help from CU Cancer Center Adrenal Cancer Multidisciplinary Team, Grace Krenrich is racing ahead with life

Jul 2, 2019

“I trust them with my life, I feel like they saved my life,” Grace says.

Saketh Guntupalli on leadership vision, higher survival rates for gynecologic cancers

Jul 1, 2019

“Care requires a balance between being aggressive to treat their cancer while also looking at them as a person,” says Saketh Guntupalli, MD.

Immune system damage may explain ineffectiveness of high-dose radiation against lung cancer

Jun 27, 2019

14.3 month vs. 28.2 month median survival for high- vs. low-dose radiation.

CU Cancer Center Deputy Director, Cathy J. Bradley, PhD, earns grant to close urban-rural cancer care gap

Jun 26, 2019

$2 million grant from the National Cancer Institute will help find actionable steps to shrink the gap between rural and urban cancer care.

How human genetic data could help dogs fight cancer

Jun 25, 2019

“We’re taking what we know from human cancers to help move canine cancer treatment forward faster,” says Dawn L. Duval,

CU Cancer Center Neuroendocrine Tumor Multidisciplinary Clinic

Jun 24, 2019

CU Cancer Center brings together more than 20 experts to offer multi-disciplinary care for patients with neuroendocrine masses.

Immunotherapy and HDAC inhibition are anti-cancer besties

Jun 24, 2019

CU study shows that adding HDAC inhibitor sensitized cancers to anti-PD1 therapy.

God doesn’t play dice. Does cancer?

Jun 20, 2019

“These mutations are disadvantageous in youth, but become advantageous later in life,” says James DeGregori, PhD.

A New Normal: Kreg’s Story

Jun 19, 2019

“When I was diagnosed with cancer for the second time I thought ‘Okay my time is limited, how can I make the most of it this?’ I decided to grow from this experience.”

Three-drug cocktail of targeted therapies promising against hormone receptor and HER2 positive metastatic breast cancer

Jun 17, 2019

Tucatinib, palbociclib and letrozole: Overall well-tolerated with promising anti-cancer activity.

OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor

Jun 17, 2019

“We successfully dosed the first patient and the patient is doing well,” says Jennifer Diamond, MD.

New Investigator Award helps Tyler Robin, MD, PhD bring new clinical trials to Colorado

Jun 5, 2019

“This award will help to bring new clinical trials to Colorado patients who could benefit.”

“Miracle drug” helps patient with recurring prostate cancer find his inner-poet

Jun 4, 2019

Clinical trial gives patient with recurring prostate cancer more time.

From hours to live to thriving: Johnna’s story

Jun 2, 2019

Johnna was near death when she arrived at the CU Cancer Center. Now she is living the life she always wanted.

ASCO: Finally, a tool to predict response to chemotherapy before bladder cancer surgery

Jun 1, 2019

“The idea is that for any individual tumor, its gene expression could tell us whether the cancer will respond to a certain kind of chemotherapy,” says Thomas Flaig, MD.

ASCO: Sexual health interventions after treatment are an unmet need for gynecologic cancer patients

May 31, 2019

“We have the opportunity to meet an unmet need with our patients,” says Lindsay Welton, MD candidate, first author on the study.

ASCO: Phase 1 clinical trials benefit patients with aggressive ovarian cancer

May 31, 2019

Phase 1 clinical trials a good option for patients with difficult ovarian cancer.

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

May 30, 2019

Brigatinib remains effective even after treatment with another next-generation ALK inhibitor

Virtual clinical trial gives entrectinib edge over crizotinib against ROS1+ non-small cell lung cancer

May 30, 2019

6 months longer progression-free survival on entrectinib vs. crizotinib

ASCO: 294 days between symptoms and diagnosis of colorectal cancer in young patients

May 29, 2019

Delays lead to late-stage diagnosis in young people with colorectal cancer

Cancer care providers see benefit in medical marijuana, but not comfortable prescribing

May 28, 2019

73% of oncology providers believe medical marijuana provides benefit, only 46% are comfortable recommending it

Insights into brigatinib’s rare side effects may help more lung cancer patients benefit from the drug

May 21, 2019

“This side effect can disappear within days despite continued exposure to the drug,” says D. Ross Camidge, MD, PhD.

CU’s Sarcoma Multidisciplinary Clinic: 20 rare cancer experts in one room

May 20, 2019

20 experts provide each patient with a personalized plan to treat their sarcoma

Tumor Host Interactions Retreat Information

May 15, 2019

2019 Olink Proteomics Pilot Award

May 14, 2019

Genomics and Microarray CoreCall for Proposals | 2019 Olink Proteomics Pilot Award Revlevant Dates:Application Deadline 5-24-2019Award Announcement ...